Moomoo report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
Why MXCT Stock dropped -8.09% Today — RQD Quant Desk Flash
MaxCyte Inc. (MXCT) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MXCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, MaxCyte Inc. (NASDAQ: MXCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.59 (-8.09% 1D, market cap $178.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MXCT ranks #682 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MXCT compare to NRC and OABI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MXCT carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.1%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and OABI (OmniAb Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MXCT?
▼
Per MXCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287098), MaxCyte Inc. generated $21.0M in revenue (-5.7% YoY), -$44.6M in net income, and -$36.2M in free cash flow against $202.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 82% of 52W Range • RSI-14 at 70.7 (OVERBOUGHT (>70))
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a MXCT Turnaround Squeeze
While MXCT currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.26) and Max Pain ($1.67) forces dealer call-delta covering toward $1.89.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why MXCT Stock dropped -8.09% Today — RQD Quant Desk Flash
MaxCyte Inc. (MXCT) dropped -8.09% to $1.59, trading at 82% of its 52-week range ($0.64 – $1.8). Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 82% of its 52-week range ($0.64 – $1.8) with RSI-14 at 70.7 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 127.9% gross margin and $0 annual free cash flow.
Benzinga report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
www.timothysykes.com report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +16.67% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of
On Thursday, there are stocks with unusual volume. Let's take a look.
https://www.sec.gov/Archives/edgar/data/1287098/000154420426000009/xslSCHEDULE_13D_X02/primary_doc.xml
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MXCT)
- ✓Walkthrough of MXCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
MXCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MXCT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MXCT. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MXCT)
1. Head-to-Head Health Care Peer Comparison (MXCT vs. NRC, OABI, ONMD, ABSI)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, MaxCyte Inc. (MXCT) ranks #682 by composite RQD confidence (35/100, grade D-) and #592 by equity capitalization ($178.5M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with MXCT at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MXCT
ACTIVE
MaxCyte Inc. | D- | 35/100 | — | 96.0% | -27.1% | -8.09% | $178.5M | Benchmark Subject |
| NRC NRC Health | C+ | 67/100 | 44.8x | — | 21.0% | +1.45% | $519.6M | /nrc-vs-mxct → |
| OABI OmniAb Inc. | D | 44/100 | — | — | -22.6% | -2.29% | $760.4M | /oabi-vs-mxct → |
| ONMD OneMedNet Corp (Class A) | E | 26/100 | — | -30.0% | -35.0% | -3.43% | $26.3M | /onmd-vs-mxct → |
| ABSI Absci Corporation | D | 45/100 | — | — | -35.0% | -8.02% | $2.08B | /absi-vs-mxct → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001287098In its most recent audited fiscal period (FY2025, filed 2025-12-31), MaxCyte Inc. (MXCT) reported GAAP revenue of $21.0M (-5.7% vs. FY2024 revenue of $22.2M , and +7.5% cumulative change since FY2023) , GAAP net income of -$44.6M, operating cash flow of -$34.4M, and free cash flow of -$36.2M (-23.6% YoY). On the balance sheet, MXCT closed FY2025 with $202.5M in total assets against $0 in total debt (Altman Z-Score: 1.52, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $21.0M | -$44.6M | -$34.4M | -$36.2M | $202.5M | — |
| FY2024 (FY) | 2024-12-31 | $22.2M | -$41.1M | -$27.6M | -$29.3M | $239.5M | — |
| FY2023 (FY) | 2023-12-31 | $19.5M | -$37.9M | -$21.7M | -$21.7M | — | — |
3. MXCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MXCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, MaxCyte Inc. (NASDAQ: MXCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.59 (-8.09% 1D, market cap $178.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MXCT ranks #682 in composite RQD confidence.
How does MXCT compare to NRC and OABI in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MXCT carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.1%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and OABI (OmniAb Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MXCT?
Per MXCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287098), MaxCyte Inc. generated $21.0M in revenue (-5.7% YoY), -$44.6M in net income, and -$36.2M in free cash flow against $202.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MXCT trading relative to its 50-day, 200-day, and 52-week technical levels?
MXCT last traded at $1.59 (-8.09% on volume of 963,830 shares), positioning the stock +26.19% above its 50-day simple moving average ($1.26) and +50.00% above its 200-day simple moving average ($1.06). Across its 52-week range of $0.64 to $1.80, MXCT sits at the 81.9% percentile with a 14-day RSI of 70.7 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($1.39 to $1.79).
MXCT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MXCT stock moving today?
Why MXCT Stock dropped -8.09% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
MXCT — MaxCyte Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, MXCT scores 35 out of 100 (letter grade D-, verdict "Roarable Sell — Vulnerable Balance Sheet & Flow"). The five pillars are:
- Fundamental cash engine (4 / 20): The rating cites ROIC of -27.1% and an FCF yield of -20.26%. Operating margin and net margin are both -60%, so the business is currently consuming cash rather than generating it. For a prospective investor, the upside case depends on a turn in operating economics that the current figures do not show.
- Whale 13F flow (15 / 20): This is the strongest pillar, reflecting institutional accumulation and options positioning. Institutional interest is a partial offset to the weak fundamentals, though it does not change the cash-flow picture.
- Insider conviction (3 / 20): The rating reflects SEC Form 4 and Congressional PTR cluster flow scored weakly. Insider signals provide limited support for the thesis.
- Macro regime fit (8 / 20): Beta of 1.0 and the sector-sensitivity assessment place MXCT in a moderate-to-weak position relative to macro conditions.
- Forensic balance sheet (5 / 20): Per the rating, Altman Z is 1.52, Piotroski F is 3/9, and Debt/Equity is 0.5. These point to a stretched financial position with limited margin for error.
Taken together, the investor implication is that the stock's low price ($1.73) and its institutional interest are offset by negative cash generation, weak forensic scores, and sub-par insider signals. Valuation tradeoffs are difficult to assess because P/E and EPS are not available in source data, so the investment case cannot be anchored to earnings. This brief is educational and not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $21.0M | $-51.9M | $-44.6M | N/A | $-36.2M | $20.1M | N/A |
| FY 2024 | $22.2M | $-51.2M | $-41.1M | N/A | $-29.3M | $27.9M | N/A |
| FY 2023 | $19.5M | $-48.3M | $-37.9M | N/A | $-21.7M | N/A | N/A |
Per the SEC financials, revenue moved from $19.5M to $22.2M and then to $21.0M across the three reported years, while operating losses widened from $-48.3M to $-51.9M. Per the market data, gross margin is 96%, while operating and net margins are both -60%, and ROIC is -27.1%. Altman Z-Score is 1.52 and Piotroski F-Score is 3/9 per the Roarable RQD rating. Cash declined from $27.9M to $20.1M over the last two reported years, and debt is reported as N/A in the financials, with Debt/Equity of 0.5 per the rating.
Recent Catalysts & News Wire Analysis
- Catalyst (GREEN): A report on MaxCyte hiring a Danaher dealmaker to drive growth, which is the only item flagged as a catalyst rather than general market wire.
- Institutional activity (YELLOW): A Stock Titan report of an investor disclosing over 5% of MXCT after October 14 share purchases.
- Market wire (YELLOW): Several items covering intraday moves, options-chain quotes, and a euro-denominated quote near EUR 1.53 on October 29.
- Proprietary signals: Not available in source data (the Butterfly graph lists none).
- Risk watch: The news flow is largely market-activity reporting; the sustainability of the revenue and loss trends is not addressed in the headlines.
Open Questions
- What are the revenue drivers behind the $19.5M to $22.2M to $21.0M trajectory, and is there a path to positive operating income?
- What is the debt structure, given that debt is reported as N/A while Debt/Equity is 0.5?
- What is the identity and cash-runway position implied by $20.1M of cash against $-36.2M of FCF?
- What is the forward earnings or EBITDA expectation, given that P/E, EV/EBITDA, and EPS are all unavailable?
- What do the 13F and Form 4 filings show in detail beyond the single >5% holder headline?
MXCT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for MaxCyte Inc. (MXCT) • Click "Debate This Headline" to argue it in the Roar Pit below
Moomoo report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
www.timothysykes.com report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering MaxCyte Inc. (MXCT) market action, institutional positioning, and fundamental catalysts.
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +16.67% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of
MXCT Bull vs. Bear Conversation Board — What's Your Call at $1.59?
🔥 Official Bull vs. Bear Debate: Is MXCT (D- • RQD 35/100) a Buy at $1.73?
Welcome to the MXCT (MaxCyte Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on MXCT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MXCT, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless MaxCyte Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MXCT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MXCT, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $1.73 (52-wk range $0.64 - $1.80), any beat on forward guidance forces shorts and underweight funds to chase.